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Abstract 
 
Objective: The degree of myocardial technetium-99m-pyrophosphate (99mTc-PYP) 
accumulation in cardiac amyloidosis is conventionally evaluated by PYP score. This 
method involves qualitative visual evaluation on two-dimensional images. Here, we 
performed three-dimensional quantitative analysis using software developed in our 
laboratory. Methods: We performed dual myocardial imaging using 
thallium-201-chloride (201Tl-Cl) and 99mTc-PYP in cases of suspected cardiac amyloidosis 
and calculated the PYP accumulation rates of all myocardial pixels showing 99mTc-PYP 
accumulation. We defined this procedure as quantitative evaluation of the degree of 
99mTc-PYP accumulation in the myocardium. Patients were divided into two groups with 
and without a diagnosis of cardiac amyloidosis, and we examined the PYP accumulation 
rates in both groups. In addition, we examined the PYP scores of the two groups by 
conventional qualitative evaluation. Results: The PYP scores of the cardiac amyloidosis 
group were significantly higher than those of the other group. The PYP accumulation 
rates of the cardiac amyloidosis group were significantly higher than those of the other 
group. There was a significant difference in the PYP accumulation rate and PYP score 
between the two groups. There was considered to be the threshold between two groups 
in the case of PYP accumulation rate. Conclusions: When the threshold of the PYP 
score was defined as 3+ and that of the PYP accumulation rate was defined as 41.5%, 
the sensitivity of the PYP score and PYP accumulation rate was 84.6%. However, the 
specificity of the PYP accumulation rate was higher than that of the PYP score. 
Quantitative evaluation by PYP accumulation rate of the degree of 99mTc-PYP 
accumulation in the myocardium may be useful in the diagnosis of cardiac amyloidosis.  
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Amyloidosis is caused by the deposition of amyloid, an insoluble protein with a fibrous 
structure, in the organs. Amyloidosis is classified as either systemic amyloidosis in 
which amyloid is deposited in many organs throughout the whole body and localized 
amyloidosis in which amyloid shows localized deposition within one organ. 
Furthermore, amyloidosis is classified into various clinical types corresponding to the 
type of amyloid protein (amyloid precursor protein). The diagnosis of amyloidosis 
depends on vital histological examination, such as biopsy. Although the biopsy site 
varies according to the clinical form, the primary sites are the gastric mucosa, duodenal 
mucous membrane, skin, subcutaneous fat at the abdominal wall and kidney.[1].  
In systemic amyloidosis, primary or myeloma merger AL amyloidosis (AL 
amyloidosis), familial amyloid polyneuropathy (FAP) I, II, and senile systemic 
amyloidosis (SSA) cause amyloid deposition in the heart and may cause cardiac 
symptoms (e.g. congestive heart failure, arrhythmia) [2-3]. However, it is rare for 
patients with secondary/responsive AA amyloidosis (AA amyloidosis) to suffer from 
serious cardiac symptoms because such cases show small amounts of amyloid 
deposition in the heart, which is often limited around blood vessels [4].  
The cardiac symptoms caused by amyloid deposition in the heart are known as 
cardiac amyloidosis. The diagnosis of cardiac amyloidosis depends on the myocardial 
biopsy. The presence or absence of cardiac amyloidosis affects the decision regarding 
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treatment strategy for systemic amyloidosis and is extremely important for prognosis. 
Therefore, a precise diagnosis of cardiac amyloidosis is essential [5]. It is important to 
consider cardiac amyloidosis in patients with suspected amyloidosis based on their 
symptoms.  
Diffuse technetium-99m-pyrophosphate (99mTc-PYP) accumulation in the heart 
in cardiac amyloidosis [2-9,13-14] is mentioned as the diagnostic reference for familial 
amyloid polyneuropathy (FAP) and is described as a supplemental diagnostic method 
for senile systemic amyloidosis (SSA) in the Guidelines for the Diagnosis of 
Amyloidosis 2011 [1]. In planar images, the degree of 99mTc-PYP accumulation in the 
myocardium (myocardial accumulation rate) is screened visually, and is judged as the 
PYP score with five phases of classification according to Falk et al. [8-9]. However, 
evaluation based on the PYP score is difficult because 99mTc-PYP accumulates at the 
ribs and calcified costal cartilage and is carried by the systemic circulation. Also, there 
has been no quantitative report on 99mTc-PYP myocardial SPECT images although there 
are qualitative reports on ones such as diffuse 99mTc-PYP accumulation or moderate 




The degree of myocardial technetium-99m-pyrophosphate (99mTc-PYP) accumulation in 
cardiac amyloidosis is conventionally evaluated by the PYP score. This method 
involves qualitative visual evaluation on two-dimensional images. Here, we performed 
three-dimensional quantitative analysis using software developed in our laboratory. 
This study received the approval of the ethics committee of Shimane University School 
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of Medicine. 
 
3. Materials and methods 
 
3-1) Study population 
 
Fifty patients (average age ±SD: 72 ± 11, men 27, women 23) with heart failure 
accompanied by left ventricular hypertrophy due to suspected cardiac amyloidosis 
underwent biopsy, echocardiography and dual myocardial imaging using 
thallium-201-chloride (201Tl-Cl) and 99mTc-PYP in our hospital between September 2007 
and May 2011. Patients were excluded from study if they suffered from ischemic heart 
disease or heart valve disease. Serum BNP (brain natriuretic peptide) was measured in 
all study subjects.  
 
3-2) Testing protocol and equipment 
 
The testing protocol was as follows: 99mTc-PYP (740 MBq) was administered to the 
subjects by IV infusion. Two hours later, 201Tl-Cl (74 MBq) was administered to the 
subjects by IV infusion. Twenty minutes later, myocardial SPECT images and front 
planar images were acquired with a dual-isotope acquisition method using a SPECT 
camera (PRISM IRIX, Philips Healthcare) and the following acquisition settings: 
collimator: low-energy, high resolution; matrix planar: 256 × 256; SPECT: 64 × 64; 
condition planar: zoom 1.48, 2 min; SPECT: zoom 1.6, 30 s/step, 5° step 360°; energy: 
74 keV ± 10% for 201TlCl, 140 keV ± 7.5% for 99mTc-PYP; image processing device: 
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Odyssey_FX. We reconfigured images in batch mode to allow acquisition of 201TlCl and 
99mTc-PYP images without a position gap. The filtered back projection method was used 
for image reconstruction, with a Butterworth preprocessing filter, ramp post-processing 
filter, and a voxel size of 2.7 × 2.7 mm. We did not perform crosstalk or scatter 
correction. Reconstructed images were transferred to a personal computer and analyzed 
using DRIP (Daemon Research Image Processor; Fuji Film Pharma) and 
SPECT_HertBlood (SPECT_HB) software developed in our laboratory. 
 
3-3) Evaluation of the degree of 99mTc-PYP accumulation in the myocardium by PYP 
score 
 
We evaluated the PYP score by five phases in the planar images of 99mTc-PYP according 
to the classification of Falk et al. as follows: 0: negative (no accumulation); 1+: slight 
99mTc-PYP accumulation compared with background; 2+: less 99mTc-PYP accumulation 
in the myocardium than in the ribs; 3+: more 99mTc-PYP accumulation in the 
myocardium than in the ribs but less than in the sternum; 4+: 99mTc-PYP accumulation 
in the myocardium equivalent or greater than that in the sternum. A circulatory organ 
specialist with experience in diagnostic imaging, such as nuclear cardiology and cardiac 
computed tomography (CT) evaluated the degree of 99mTc-PYP accumulation by 
monitor diagnosis. Prior to evaluation and analysis, patients were divided into a group 
diagnosed with cardiac amyloidosis by biopsy (Direct Fast Scarlet stain, potassium 
permanganate test, polariscopy, immunostaining) and ultrasonography[1] and another 
group which was not diagnosed with cardiac amyloidosis. We defined the former as the 
cardiac amyloidosis group and the latter as the other group. The statistical method 
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appropriate to the data of the two groups was used to examine the 5% of hazard ratios 
for determining the significance of the differences in PYP scores between the two 
groups. The diagnosis of cardiac amyloidosis by ultrasonography depends on whether 
there is cardiac hypertrophy, if the left ventricular wall and interventricular septum are 
hypertrophied by more than 12 mm, or there is a granular sparkling appearance, 
hyperechoic spot or Left ventricle ejection fraction (LVEF). In addition, when a case 
was not diagnosed as cardiac amyloidosis, we did not judge the case to be cardiac 
amyloidosis even though amyloid was identified by biopsy. 
  
3-4) Evaluation of the degree of 99mTc-PYP accumulation in the myocardium by PYP 
accumulation rate 
 
Figure 1 shows the procedure used for quantitative evaluation. We extracted the left 
ventricular and myocardial region from the 201Tl-Cl SPECT short axis images using 
DRIP and then made an image mask. We set the threshold manually from the mask 
image using SPECT_HB and made a binarized image, and then identified the  
ventricular cavity and myocardium. We applied the identified three-dimensional region 
to the 99mTc-PYP SPECT short axis images. When the myocardial count was 0.93 or 
more times higher than the ventricular cavity mean count in the 99mTc-PYP SPECT 
short axis image, we identified 99mTc-PYP accumulation in the myocardium and then 
calculated the pixels. We calculated the rate of myocardial pixels judged for 99mTc-PYP 
to accumulate for total pixel number in the myocardium and the PYP accumulation 
rate. This procedure represented a quantitative evaluation of the degree of 99mTc-PYP 
accumulation in the myocardium. We divided the subjects into the cardiac amyloidosis 
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group and the other group, and examined the degree of 99mTc-PYP accumulation in the 
myocardium as well as the PYP score in both groups. The method suitable for the data 
of the two groups was used to examine the 5% hazard ratios to determine the 
significance of the differences in PYP accumulation rate between the two groups. A 
specialist in nuclear medicine analyzed the degree of 99mTc-PYP accumulation in the 
myocardium by SPECT_HB in the presence of the circulatory organ specialist who 
performed the PYP score analysis. In addition, we identified 99mTc-PYP accumulation 
when the myocardial count was 0.93 or more times higher than the mean count in the  
ventricular cavity, as will be described in the next section. 
 
3-5) Rationale for identification of 99mTc-PYP accumulation when myocardial count is 
0.93 or more times higher than the mean count in the ventricular cavity 
 
When we identified 99mTc-PYP accumulation in the myocardium, we calculated the ratio 
of the myocardial mean count to the ventricular cavity mean count (the PYP count ratio) 
in 50 patients. The average ± SD of the PYP count ratio in the cardiac amyloidosis 
group was 1.28 ± 0.31, while that of the other group was 0.795 ± 0.066 (Fig. 2). The 
PYP count ratio in the cardiac amyloidosis group and the other group showed a normal 
distribution and the population variance was unequal in both groups (F-test). Therefore, 
using Welch’s t test, we examined the 5% hazard ratios to determine whether the 
population means of the two independent groups were significantly different. The 
results indicated a significant difference between the two groups (P < 0.05), with the 
PYP count ratio in the cardiac amyloidosis group being greater than that of the other 
group. Therefore, the threshold of the PYP count ratio between the two groups was 0.93 
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(0.795 + 2 × 0.066); the value 0.93 included approximately 95% of the normal group, 
0.795 was the average PYP count ratio of the other group, and 0.066 was the SD. 
Therefore, we identified 99mTc-PYP accumulation in the myocardium when the 
myocardial count was 0.93 or more times higher than the ventricular cavity mean count.  
 
3-6) Calculating the odds ratio 
 
We determined the positive/negative threshold, the threshold of the PYP score and the 
PYP accumulation rate between the cardiac amyloidosis group and the other group. We 
then made a 2×2 contingency table and calculated the positive odds ratio in the cardiac 




4-1) Clinical findings of the cardiac amyloidosis group and the other group 
 
Table 1 shows the clinical evidence of 13 cases of the cardiac amyloidosis group and 5 
cases of other groups. Of the 50 patients, 13 were diagnosed as having cardiac 
amyloidosis consisting of one case of AL amyloidosis, three of familial amyloid 
polyneuropathy, eight of senile systemic amyloidosis, and one of AA amyloidosis. The 
other group consisted of 37 cases. Three patients in the other group (Case 15-17) had 
AA amyloidosis and one patient (Case 14) had AL amyloidosis, but which was not a 
morbid condition of a cardiac amyloidosis. We listed Case 14-17 in Table 1. This is 
because these cases were diagnosed as amyloidoses although these cases belong to the 
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other group. In addition, we listed Case 18 in Table 1. This is because PYP score of 
Case 18 is bigger than that of the other cases which belong to the other group. Table 2 
shows the echocardiographic data and serum BNP. of the cardiac amyloidosis group and 
the other group. 
 
4-2) PYP scores of the cardiac amyloidosis group and the other group 
 
Figure 3 shows the PYP scores of the cardiac amyloidosis group and the other group. 
The cardiac amyloidosis group included one case with a PYP score of 1+, one case with 
a PYP score of 2+, two cases with PYP scores of 3+ and nine cases with scores of 4+ 
(average ± SD: 3.4 ± 0.9). In the other group, 23 cases had PYP scores of 0, 1 had a 
score of 1+, 2 had scores of 2+, and 2 had scores of 3+ (average ± SD: 0.5 ± 0.8). The 
Mann–Whitney U test was used to examine the 5% of hazard ratios to determine the 
significance of the differences in PYP scores between the two groups, because the PYP 
scores represent discrete data. The PYP scores of the cardiac amyloidosis group were 
significantly higher than those of the other group (P < 0.05). 
 
4-3) The PYP accumulation rates in the cardiac amyloidosis group and the other group 
 
The average ± SD of the PYP accumulation rates of the cardiac amyloidosis group was 
80.8 ± 28.0%, while that of the other group was 19.8 ± 10.85% (Fig. 4). The 
Mann–Whitney U test was used to examine the 5% of hazard ratios to determine the 
significance of the differences in the median of the distribution between the two 
populations. The results indicated that the PYP accumulation rates in the myocardium 
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were significantly higher in the cardiac amyloidosis group than in the other group (P < 
0.05). 
 
4-4) Odds ratio 
The threshold of the PYP accumulation rate was considered to be the sum of the average 
degree of 99mTc-PYP accumulation and double SD, 41.5 (19.8 + 10.85×2) %.  
According to Falk et al., the threshold of the PYP score was considered to be over 3+. 
We then made a 2×2 contingency table, which is shown in Table 3. In the cardiac 
amyloidosis group, the positive odds ratio was 1. This means that the possibility of 
judging a case to be positive from PYP score is equal to that from the PYP accumulation 
rate. In contrast, negative odds ratio was 2.05. This means the possibility of judging a 





There were 4 cases of AA amyloidosis (Case 9, 15, 16, 17) among the 50 patients. In 
these cases, the 99mTc-PYP accumulation in the myocardium was predicted to be smaller 
than in the cases of the other amyloidosis. However, the PYP accumulation rate of Case 
9 was 62.58%. This score was larger than expected. Case 9 shows the morbid condition 
of cardiac amyloidosis (chronic congestive heart failure) and was considered to be 
advanced AA amyloidosis accompanied by cardiopathy [1]. Case 15, 16, 17 were not 
cardiac amyloidosis. However, in the case of AA amyloidosis, it has been reported that 
there was no 99mTc-PYP accumulation in the myocardium even though there was 
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amyloid accumulation in the heart and patients presented with symptoms of congestive 
heart failure [4, 13-14]. It is difficult to detect cardiopathy using 99mTc-PYP in these 
cases. Therefore, care is required in the case of AA amyloidosis and Case 15, 16, and 17 
should receive careful follow-up. Follow-up by evaluating the PYP accumulation rate is 
considered to be useful in these cases. 
In the cardiac amyloidosis group, Case 12 (39.83%) and Case 13 (10.06%) were 
determined to be senile systemic amyloidosis. Smirnov–Grubbs testing indicated that 
the PYP accumulation rate in Case 12 and 13 were outliers and were significantly 
smaller than those of the other cardiac amyloidosis cases. This means that little amyloid 
was deposited in the heart. In the cases of senile systemic amyloidosis, patients are 
considered to suffer from cardiomyopathy even though amyloid deposition in the heart 
is low. In addition, when we collect more data on the PYP accumulation rates in senile 
systemic amyloidosis, we may observe a clearer relation between cardiopathy and the 
degree of 99mTc-PYP accumulation. This is because the PYP accumulation rate is not 
discrete data. 
In the cardiac amyloidosis group, Case 2 (99.87%), Case 3 (96.11%) and Case 6 
(99.66%) were familial amyloid polyneuropathy. Fujii et al. have reported that the 
patients with familial amyloid polyneuropathy showed complete or partial defects in 
their 123I-metaiodobenzylguanidine (123I-MIBG) myocardial images [7]. We could 
calculate the rates of 123I-MIBG accumulation in the myocardium of such cases. 
In the other group, the PYP accumulation rate of Case 14 was 53.64% (PYP score was 
0). Case 14 was diagnosed as multiple myeloma. We supposed that AL amyloidosis 
complicated with myeloma developed in Case 14 and this patient would have eventually 
developed cardiac amyloidosis. In addition, Smirnov–Grubbs testing indicated that the 
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PYP accumulation rate in Case 14 was an outlier and was significantly greater than 
those of the other cases in the other group. In this case, the PYP accumulation rate is 
considered to be more useful than the PYP score.  
We examined the relations of a significantly different heart function index (cf. table 2) 
in a PYP accumulation rate and cardiac amyloidosis group and other groups. There is 
weak negative correlation between PYP accumulation rate and LVEF. There is weak 
negative correlation between PYP accumulation rate and FS. There is weak negative 
correlation between PYP accumulation rate and DT. There is negative correlation 
between PYP accumulation rate and A. There is weak positive correlation between PYP 
accumulation rate and IVSth. There is weak positive correlation between PYP 
accumulation rate and LV mass index. There is positive correlation between PYP 
accumulation rate and PWth. There is positive correlation between PYP accumulation 
rate and E/A. 
The sensitivity and specificity of the PYP accumulation rate were 84.6% and 97.3%, 
respectively and the sensitivity and specificity of the PYP score were 84.6% and 94.5%, 
respectively (Table 3). The specificity of the PYP accumulation rate was higher than 
that of the PYP score. Thus, quantitative evaluation by the PYP accumulation rate is 
considered to be more useful than the PYP score for diagnosis of cardiac amyloidosis. 
The sensitivity was higher than in previous reports [3-5, 8-9]. This is because in our 
study group of 50 patients, there were many senile systemic amyloidosis whose PYP 
accumulation rate is considered to be high [1], and few cases of AA amyloidosis and AL 
amyloidosis. 
 
Figure 6 shows Case 9 and Case 18. The PYP score of Case 9 and that of Case 18 were 
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3+. Case 9 belongs to the cardiac amyloidosis group (AA amyloidosis) and had an 
accumulation rate of 62.59%. Case 18 belongs to the other group and had a PYP 
accumulation rate of 13.15%. When we compared 201Tl-Cl myocardial SPECT images 
with 99mTc-PYP myocardial SPECT images, we found that 99mTc-PYP accumulated in 
the myocardium in Case 9 and 99mTc-PYP accumulated in the ventricular cavity in Case 
18. It was difficult to diagnose Case 18 from the 99mTc-PYP planar images. Therefore, 
dual-isotope simultaneous acquisition (SPECT image) is useful in this case. In addition, 
in this case the PYP accumulation rate, which represents objective continuance data, 
was considered to be more useful than the PYP score which is a subjective discrete 
value. 
In the 201Tl-Cl myocardial SPECT images of Case 4, 5, 8 which belong to the cardiac 
amyloidosis group, 201Tl-Cl accumulation decreases at the site where 99mTc-PYP 
strongly accumulates. We showed 99mTc-PYP myocardium images and 201Tl-Cl 
myocardium images of case 5 in Figure 7. In the 201Tl-Cl myocardial SPECT images of 
the other cases, decreases in 201Tl-Cl accumulation were not apparent. This finding has 
also been reported [6-7, 13-14] and indicates that there may be degeneration and 
sloughing off of cardiac muscle cells because of amyloid deposition, as suggested by 
Imamoto et al. [6]. This finding could not be acquired only by 99mTc-PYP planar images. 
Thus, dual-isotope simultaneous acquisition (SPECT image) is considered to be useful 
in identifying this situation. 
 
As shown in Figure 8, analyses of all 50 cases revealed a positive correlation between 
the PYP score and the PYP accumulation rate by the Spearman correlation coefficient 
by rank test (correlation coefficient = 0.69). The PYP score is discrete data and the PYP 
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accumulation rate does not show a normal distribution. The PYP accumulation rate is 
related to the PYP score and is considered to be a useful new method for evaluation of 
the degree of 99mTc-PYP accumulation in the myocardium. 
 
We acquired images of 29 patients at 2 hours 20 minutes after (First) and 5 hours or 
more after (Second) the administration of 99mTc-PYP. Then, we calculated the PYP 
count ratios of the First and Second acquisitions. The PYP count ratio of the First 
acquisition was 0.82±0.18 and that of the Second acquisition was 0.84±0.16. The 
Wilcoxon signed-ranks test was used to examine the 5% of hazard ratios to determine 
the significance of the differences in the median of the 2 groups. This is because the 
data of the 2 groups do not show a normal distribution. The results indicated that there 
was a significant difference (P =0.04< 0.05). Therefore, when the time from 
administration of 99mTc-PYP to image pickup is different, the threshold is considered to 
be different. In addition, the threshold is considered to depend on the equipment, the 
image acquisition parameters and the image reconstruction parameters. These problems 
must be examined in future. 




We performed dual myocardial imaging using 201Tl-Cl and 99mTc-PYP in cases of 
suspected cardiac amyloidosis and performed a quantitative evaluation of the degree of 
99mTc-PYP accumulation in the myocardium. There was a significant difference in the 
PYP accumulation rate in the myocardium between the cardiac amyloidosis group and 
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the other group. Therefore, we supposed that there was a threshold between the two 
groups, and quantitative evaluation of the degree of 99mTc-PYP accumulation in the 
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List of Figures 
Figure 1 
Procedure for quantitative evaluation using SPECT_HB. 
We made left ventricular myocardial mask images from 201TlCl images using DRIP. We 
used a threshold variable and mask images were binarized into the ventricular cavity 
and myocardium. The mask was applied to the 99mTc-PYP images using the coordinates 
of the myocardium and ventricular cavity. Finally, we quantitatively analyzed the 
myocardium and ventricular cavity on a voxel-by-voxel basis from the 3D coordinate 
axis. When the myocardial count was 0.93 or more times higher than the ventricular 
cavity count, we identified 99mTc-PYP accumulation in the myocardium. We calculated 
the rate of myocardial pixels judged positive for 99mTc-PYP as an indicator of 




“ The PYP count ratio “ of the cardiac amyloidosis group and the other group. 
The cases are shown on the transverse axis (the cardiac amyloidosis group is shown on 
the left and the other group is on the right) and the PYP count ratio is shown on the 
vertical axis. 
The PYP count ratio of the cardiac amyloidosis group was significantly higher than that 
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Figure 3 
PYP scores of the cardiac amyloidosis group and the other group. 
The cases are shown on the transverse axis (the cardiac amyloidosis group is shown on 
the left and the other group is on the right) and the PYP scores are shown on the vertical 
axis. 
The PYP scores of the cardiac amyloidosis group were significantly higher than those of 
the other group (P < 0.05). 
 
Figure 4 
The PYP accumulation rates of the cardiac amyloidosis group and the other group. 
The cases are shown on the transverse axis (the cardiac amyloidosis group is shown on 
the left and the other group is on the right) and the PYP accumulation rates (%) is 
shown on the vertical axis. 
The PYP accumulation rates of the cardiac amyloidosis group were significantly higher 
than those of the other group (P < 0.05). 
 
Figure 5 
Relations of PYP accumulation rate and LVEF  
Pearson’s product-moment correlation coefficient:  r = -0.36 ( n = 49 , P < 0.05 ) 
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Figure 6 
99mTc-PYP planar image, 99mTc-PYP SPECT image, 201TlCl SPECT image and dual 
isotope image of Case 9 and Case 18. 
(a) Case 9 (PYP score is 3+) belongs to the cardiac amyloidosis group. 99mTc-PYP 
accumulation in the myocardium shown in the 99mTc-PYP planar image and 99mTc-PYP 
SPECT image is confirmed from  the 201TlCl SPECT image and dual isotope image. 
(b) Case 18 (PYP score is 3+) belongs to the cardiac amyloidosis group. 99mTc-PYP 
accumulation in the ventricular cavity shown in the 99mTc-PYP planar image and 
99mTc-PYP SPECT image is confirmed from the 201TlCl SPECT image and dual isotope 
image. 
In the dual isotope images, dark gray shows 201TlCl accumulation (1), light gray shows 




99mTc-PYP myocardium images and 201Tl-Cl myocardium images of case 5 
99mTc-PYP strongly accumulates in the base side of the posterior wall of a ventricular 
septum. 







Novel quantitative cardiac amyloidosis evaluation method 
Figure 8 
PYP accumulation rates and PYP scores of each group 
PYP scores from 0 to 4+ are shown on the transverse axis with the corresponding PYP 
accumulation rates shown on the vertical axis. (○, cardiac amyloidosis group; ●, the 
other group). 




List of cases of the cardiac amyloidosis group and the other group 
Clinical form and clinical findings of Cases 1–13 in the cardiac amyloidosis group and 
Cases 14–18 in the other group 
AA: AA amyloidosis (secondary amyloidosis) 
AL: AL amyloidosis (primary amyloidosis) 
FAP: familial amyloid polyneuropathy 
SSA: senile systemic amyloidosis 
EF: left ventricular ejection fraction 
IVSth: thickness of interventricular septum 







Novel quantitative cardiac amyloidosis evaluation method 
Table 2 
Myocardial scintigraphic findings, echocardiographic analysis data and serum BNP 
levels 
LVDd: left ventricular internal dimension in diastole 
LVDs: left ventricular internal dimension in systole 
FS: fractional shortening 
EF (Teichholz method): left ventricular ejection fraction 
LVMI (g/m2): left ventricular mass index 
LAD: left atrial dimension 
E: peak early diastolic left ventricular filling velocity 
A: peak atrial filling velocity 
E/A: peak early diastolic left ventricular filling velocity/peak atrial filling velocity ratio 
DT: deceleration time 
IVRT: isovolumetric relaxation time 
E/E`: the ratio of deceleration time of early diastolic wave to mitral valve ring velocity 
BNP: brain natriuretic peptide 
 
Table 3 
Odds ratios of PYP score and PYP accumulation rate 
In the cardiac amyloidosis group, positive odds ratio was 1. In the other group, negative 
odds ratio was 2.05.  
 
Binarization
（201Tl-Cl Mask）201Tl-Cl 99mTc-PYP× 201Tl-Cl Mask
SPECT_HB










































































































































































Case Age(yr) & Sex
Clinical 
findings biopsy site
99mTc-PYP  uptake Echocardiogram
PYP myocardial 
accumulation rate (%) PYP score EF(%)
IVSth 
(mm) PWth (mm)
1 46M AL duodenum 98.42 3+ 42 13 13
2 56F FAP myocardium 99.87 4+ 30 18 18
3 60F FAP skin ,mesopharynx 96.11 4+ 59 11 12
4 83F SSA skin,duodenum ,stomach,aorta 98.37 4+ 58 8 15
5 87M SSA skin 79.97 4+ 50 15 15
6 74F FAP skin 99.66 4+ 61 17 16
7 79M SSA myocardium ,Kidney,skin 99.98 4+ 57 14 13
8 90M SSA skin 76.00 4+ 50 16 16
9 53F AA skin 62.59 3+ 59 19 20
10 80M SSA myocardium 99.83 4+ 66 13 13
*11 90F SSA gallbladder 89.95 4+ 60 11 12
12 78M SSA subcutaneous tissue, abdominal wall fat 39.83 2+ 56 15 14
13 81M SSA blood vessel 10.06 1+ 52 15 15
!4 69F AL Kidney, duodenum ,stomach 53.65 0 71 11 10
15 64F AA blood vessel 33.09 1+ 67 13 12
16 82F AA duodenum ,stomach, 9.59 0 60 12 11
17 34F AA Kidney 10.97 1+ 74 8 8
18 68F Myocardium, skin 13.15 3+ 64 11 13
*Case11:granular sparkling appearanceTable.1 
Amyloidosi group Other group p-Value
Number of cases n = 13 n = 37
Age 73.6±14.8 71.8±10.9 P = 0.41
Men 7 20
Female 6 17
LVDd(mm) 44.3±6.0 45.3±6.0 P = 0.71
LVDs( mm) 32.0±5.4 29.7±6.7 P = 0.26
FS(%) 28±5.7 35±7.9 P < 0.05
EF (Teichholz)  % 53.8±9.4  (n=13) 63.8±11.0  (n=36) P < 0.05
IVSth  mm 14.2±3.0 11.9±2.2 P < 0.05
PWth  mm 14.7±2.3 11.1±1.8 P < 0.05
LV mass index(g/m2) 177.5±47.5  (n=11) 135.9±42.7  (n=29) P < 0.05
LAD (mm) 43.2±8.6 40.3±7.0 P = 0.23
EF (Simpson methods） % 50.2±12.7  (n=9) 58.7±13.8  (n=22) P = 0.12
E (cm/sec) 76.2±21.8 67.2±21.3 P = 0.19
A (cm/sec) 50.3±31.0  (n=8) 92.6±23.7  (n=32) P < 0.05
E/A 2.2±1.6  (n=8) 0.72±0.28  (n=32) P < 0.05
DT (msec) 160.8±39.5  (n=12) 231.6±71.3  (n=35) P < 0.05
IVRT (msec) 83.0±21.5  (n=6) 81.2±15.1  (n=7) P = 0.86
E/E'  (E/Ea) 22.1±9.8  (n=9) 17.8±8.4  (n=29) P = 0.55
BNP (pg/ml) 540.7±464.3  (n=13) 361.4±433.5  (n=36) P = 0.11
PYP accumulation rate(%) 80.8±28.0 19.8±10.8 P < 0.05
PYP score 3.4±0.9 0.5±0.8 P < 0.05
Table.2
Amyloidos group Other group
Positivity 11 1
Negative 2 36
Amyloidosi group Other group
Positivity 11 2
Negative 2 35
(b)PYP myocardial  accumulation rate (%)(a)PYP score
Table.3
